For Hemophilia A
Synthetic factor VIII made using recombinant DNA technology. First-line for Hemophilia A. Brands include Advate, Kogenate, Eloctate (extended half-life).
For Hemophilia B
Synthetic factor IX product. Preferred in Hemophilia B. Extended half-life versions (e.g., Alprolix, Idelvion) reduce infusion frequency.
Alternative for Hemophilia A or B
Made from donated human plasma. May carry a small risk of viral transmission. Includes von Willebrand factor in some formulations.
For Hemophilia A (with or without inhibitors)
A bispecific monoclonal antibody that mimics factor VIII function. Administered subcutaneously, typically weekly or every 2–4 weeks. Reduces bleeding episodes significantly.
For Hemophilia A or B with inhibitors
Promotes clot formation independently of factor VIII or IX. Used for acute bleeding or surgery. Brand: NovoSeven.
For Hemophilia A or B with inhibitors
Contains activated clotting factors that bypass the need for factor VIII/IX. Used in on-demand or prophylactic regimens. Brand: FEIBA.
For mild Hemophilia A
Stimulates release of stored factor VIII and von Willebrand factor. Administered IV or intranasally. Not useful for Hemophilia B or severe cases.
Supportive
Prevents breakdown of clots. Useful in mucosal bleeding, dental procedures, or menorrhagia. Often used alongside other therapies.
For Hemophilia B
FDA-approved gene therapy delivering a functional copy of the factor IX gene via an AAV vector. One-time IV infusion. May reduce/eliminate need for further factor therapy.
For Hemophilia A
Experimental gene therapy using an AAV5 vector to deliver factor VIII gene. Demonstrates long-term FVIII expression in some patients.
Stay updated with the latest news, events, and important updates from our community. Subscribe to our newsletter and never miss out on valuable insights, upcoming activities, and special announcements delivered straight to your inbox.
